肝硬化门静脉血栓防治的新靶点
New targets for the prevention and treatment of cirrhotic portal vein thrombosis
王宇威 1丁惠国1
作者信息
- 1. 首都医科大学附属北京佑安医院肝病消化中心,北京 100000
- 折叠
摘要
门静脉血栓(PVT)分为肝硬化性PVT和非肝硬化性PVT.PVT发病率在肝硬化不同临床阶段差别较大,总体发病率约为13.92％,而肝硬化脾切除术后PVT患病率高达60％.肝硬化性PVT的发病机制尚不明确,但Janus激酶/信号转导与转录激活子信号通路活化、血管性血友病因子表达增加、肠道菌群及其代谢产物三甲胺-N-氧化物在肝硬化血管内皮细胞损伤、PVT形成中具有重要作用,可能是肝硬化性PVT防治的新靶点.
Abstract
Portal vein thrombosis(PVT)is divided into cirrhotic and non-cirrhotic PVTs.The incidence rate of PVT varies greatly among different clinical stages of cirrhosis,with an overall incidence rate of about 13.92％,and the prevalence of cirrhotic PVT following splenectomy is as high as 60％.The pathogenesis of cirrhotic PVT is still unclear.However,the activation of Janus kinase/signal transduction and activator transcription signaling pathways,the rise in the expression of von Willebrand factor,and the gut microbiota along with its metabolite trimethylamine-N-oxide play an important role in the injury of vascular endothelial cells and the formation of PVT in cirrhosis.Therefore,these could be a new target for cirrhotic PVT prevention and treatment.
关键词
肝硬化/门静脉血栓/治疗/危险因素/肠道菌群/预防/靶点Key words
Liver cirrhosis/Portal vein thrombosis/Treatment/Risk factors/Intestinal flora/Prevention/Target point引用本文复制引用
基金项目
首都卫生发展科研专项项目(2022-1-2181)
首都特色诊疗技术研究及转化应用重点专项(Z221100007422002)
出版年
2024
NETL
NSTL
万方数据